导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -21.97% | 4456/4773 |
| 近一周 | -4.85% | 5127/5462 |
| 近一月 | -6.03% | 3423/5421 |
| 近一季 | -3.46% | 1412/5209 |
| 近半年 | -16.80% | 4119/4920 |
| 近一年 | -26.15% | 4100/4366 |
| 近两年 | 40.75% | 1859/2954 |
| 近三年 | -0.84% | 1941/2253 |
| 成立以来 | 12.06% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.19% 4627/4961 |
-7.78% 3805/5312 |
- - |
- - |
| 2025 | 14.85% 2588/4813 |
1.80% 1545/3635 |
9.08% 298/4076 |
9.51% 3351/4524 |
-5.56% 3569/4813 |
| 2024 | 17.53% 679/3463 |
-9.22% 2273/2808 |
-12.79% 2611/3014 |
34.25% 80/3129 |
10.59% 261/3463 |
| 2023 | -0.53% 459/2656 |
24.60% 102/2280 |
-7.85% 1921/2385 |
-7.97% 1650/2515 |
-5.87% 1536/2655 |
| 2022 | -20.23% 945/2207 |
-13.79% 837/1919 |
-5.83% 1875/2016 |
-14.80% 1148/2113 |
15.33% 69/2208 |
| 2021 | 3.41% 612/1822 |
-8.84% 1096/1255 |
9.72% 528/1330 |
-4.84% 740/1466 |
8.65% 144/1822 |
| 2020 | - - |
- - |
- - |
-3.21% 1089/1164 |
-0.98% 1089/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 合煦智远金融科技指数(LOF)C VS. 长安沪深300非周期A(740101) |